Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association.

MLA

van den Beukel, Michelle D., et al. “Antibodies against Advanced Glycation End-Products and Malondialdehyde-Acetaldehyde Adducts Identify a New Specific Subgroup of Hitherto Patients with Seronegative Arthritis with a Distinct Clinical Phenotype and an HLA Class II Association.” RMD Open, vol. 9, no. 4, Dec. 2023, pp. 1–11. EBSCOhost, https://doi.org/10.1136/rmdopen-2023-003480.

APA

van den Beukel, M. D., van Wesemael, T. J., Hoogslag, A. T. W., Borggreven, N. V., Huizinga, T. W. J., van der Helm-van, A. H. M., Toes, R. E. M., van der Woude, D., & Trouw, L. A. (2023). Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association. RMD Open, 9(4), 1–11. https://doi.org/10.1136/rmdopen-2023-003480

Chicago

van den Beukel, Michelle D., Tineke J. van Wesemael, Anna Titia W. Hoogslag, Nicole V. Borggreven, Tom W. J. Huizinga, Annette H. M. van der Helm-van, René E. M. Toes, Diane van der Woude, and Leendert A. Trouw. 2023. “Antibodies against Advanced Glycation End-Products and Malondialdehyde-Acetaldehyde Adducts Identify a New Specific Subgroup of Hitherto Patients with Seronegative Arthritis with a Distinct Clinical Phenotype and an HLA Class II Association.” RMD Open 9 (4): 1–11. doi:10.1136/rmdopen-2023-003480.